GSK's RSV vaccine candidate, Phase I/II, achieved positive results

candidate vaccine for respiratory syncytial cytovirus in GlaxoSmithKline has achieved some positive results in phase I/II studies.The data came from early studies of candidates for respiratory syncytial virus vaccines for GlaxoSmithKline (GlaxoSmithKline 3888550A) and the elderly (GlaxoSmithKline 3844766A).According to GlaxoSmithKline, both candidates were well-resistant and highly immunogenic in the Phase I/II study.The candidate vaccine for respiratory syncytial virus in pregnant women and adults contains recombinant pre-respiratory syncytial virus antigens, which are believed to trigger an immune response.In addition, vaccines for the elderly include GlaxoSmithKline's proprietary AS01 ad adhesive system, which enhances the immune response of the population because older people are less immune to the vaccine than younger people.Respiratory syncytial viruses are the main cause of respiratory infections in infants and the elderly, including fine bronchitis and pneumonia. It is estimated that about 3 million children under the age of five are hospitalized each year for respiratory syncytial virus, and in the United States alone, 1,777,000 elderly people are hospitalized.“ We are pleased to see these positive results, confirming our approach to developing specialized vaccines based on the strategic use of platform technology for people most at risk of respiratory syncytial virus infection (infants and the elderly)," said Emmanuel Hanon, Director/Senior Vice President and CEO, GlaxoSmithKline Vaccine Research and Development.He added: "Our portfolio strategy considers the unique needs of these vulnerable populations and we look forward to developing these assets to Phase III clinical trials to assess their potential efficacy." Afterpositive results in Phase I/II, GlaxoSmithKline plans to move the candidates to Phase III, which is currently being prepared and will begin in the coming months. (cyy123.com)original source: